Harmonizing PD-L1 testing in metastatic triple negative breast cancer

Expert Opin Biol Ther. 2022 Mar;22(3):345-348. doi: 10.1080/14712598.2022.2021180. Epub 2021 Dec 29.

Authors

Federica Giugliano^{1

2}, Gabriele Antonarelli^{1

2}, Paolo Tarantino^{1

2}, Javier Cortes³, Hope S Rugo⁴, Giuseppe Curigliano^{1

2}

Affiliations

¹ European Institute of Oncology, IRCCS, Milan, Italy.
² Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy.
³ International Breast Cancer Center (IBCC), Quironsalud Group, Madrid & Barcelona, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
⁴ University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

PMID: 34930070
DOI: 10.1080/14712598.2022.2021180

No abstract available

Keywords: Immunohistochemistry; PD-L1; immunotherapy; metastatic breast cancer; triple negative.

Publication types

Editorial

MeSH terms

B7-H1 Antigen*
Biomarkers, Tumor
Humans
Immunotherapy
Triple Negative Breast Neoplasms* / diagnosis
Triple Negative Breast Neoplasms* / genetics
Triple Negative Breast Neoplasms* / pathology

Substances

B7-H1 Antigen
Biomarkers, Tumor